Skip to main content

Table 2 Characteristics of included studies in the meta-analysis (no MSCs group)

From: Mesenchymal stromal cells as prophylaxis for graft-versus-host disease in haplo-identical hematopoietic stem cell transplantation recipients with severe aplastic anemia?—a systematic review and meta-analysis

Author (publication year)

Study design

Recruitment period

Number of patients

Median age

Sex (M/F)

Type

Conditioning regimen

GVHD prophylaxis

Interval from diagnosis to treatment (M)

Neutrophil recovery (d)

Platelet engraftment

MSCs originals

NOS score

Zhang YY [56] (2020)

Single-arm study

January 2013-Septemper 2018

35

43 (40–54)

23/11

SAA/VSAA (19/16)

BU + CY + ATG

CsA + MMF + MTX

NA

13 (9–21)

17 (10–102)

NA

6

Ma YR [55] (2020)

Single-arm study

NA

199

NA

106/93

NA

BU + CY + ATG

CsA + MMF + MTX

NA

NA

NA

NA

6

Liu LM [54] (2020)

Single-arm study

Septemper 2010-Septemper 2018

16

32 (8–55)

9/7

NA

ATG + rituximab

NA

NA

11 (9–20)

21 (13–112)

NA

6

Yang SW [22] (2019)

Single-arm study

NA

32

NA

21/11

NA

NA

NA

NA

NA

NA

NA

6

Xu LP5 [53] (2019)

Single-arm study

2006–2018

392

NA

223/167

NA

BU + CY + ATG

CsA + MMF + MTX

NA

12 (9–31)

14 (5–180)

NA

6

Hyery Kim [52] (2019)

Single-arm study

2008–2017

32

12.7 (1.4–21.7)

22/10

SAA/VSAA (20/12)

FLU, CY, ATG ± TBI

CsA + MMF

5.2 (1.2–106.8)

10 (9–30)

15.5 (13–60)

NA

5

Lu Y [51] (2018)

Single-arm study

Septemper 2012-Septemper 2016

41

13 (4–42)

25/16

SAA/VSAA(28/13)

FLU, CY, ATG

CsA + MMF + MTX

25 (6–45)

14 (10–21)

13 (3–56)

NA

6

Sung-Eun Lee [24] (2018)

Single-arm study

June 2012-December 2016

34

31.5 (17–59)

20/14

SAA/VSAA (11/23)

ATG + TBI + FLU

CsA + MTX

NA

12 (11–12)

14 (5–86)

NA

5

Cheng YF [50] (2018)

Single-arm study

December 2007-Septemper 2016

28

NA

NA

NA

NA

NA

2.75 (1–8)

12 (10–21)

NA

NA

6

Cao LQ [49] (2018)

Single-arm study

January 2006-December 2016

131

16 (2–45)

70/61

NA

NA

NA

NA

12 (10–31)

16 (7–276)

NA

5

Zhang P [48] (2017)

Single-arm study

June 2014-December 2015

8

14 (5–26)

5/3

NA

FLU, CY, ALG/TBI

CsA + MMF + MTX

NA

14.8 (11–20)

15.0 (11–21)

NA

6

Zhang Y [47] (2017)

Single-arm study

June 2010-December 2014

18

NA

NA

NA

NA

NA

NA

16 (12–26)

20 (17–35)

NA

5

Pei XY [46] (2017)

Single-arm study

January 2008-December 2015

81

14 (3–45)

50/31

SAA/VSAA (63/18)

NA

NA

NA

12 (10–22)

15 (7–150)

NA

6

Sarita Rani Jaiswal [45] (2017)

Single-arm study

January 2015-May 2016

20

NA

NA

NA

FLU, CY, ATG, melphalan

PTCy + sirolimus + CsA + MMF (abatacept)

NA

NA

NA

NA

5

Amy E. DeZern [44](2017)

Single-arm study

July 2011-August 2016

13

33 (11–69)

9/5

NA

FLU, CY, ATG ± TBI

PTCy+MMF + FK506

NA

19 (16–27)

28 (22–108)

NA

5

Zhu H [43] (2016)

Single-arm study

July 2002-November 2013

38

NA

12/24

SAA/VSAA (8/28)

FLU, CY, ATG ± TBI/BU

CsA + methotrexate (MTX) (n = 12) CsA + MTX + mycophenolate mofetil (MMF) (n = 22) MTX + tacrolimus (n = 4)

NA

NA

NA

NA

6

Liu L [42] (2016)

Single-arm study

July 2005-December 2013

26

26 (10–54)

15/11

SAA/VSAA/(16/6)

NA

NA

NA

12 (6–28)

19 (12–330)

NA

5

Ho Joon Im [41] (2015)

Single-arm study

NA

21

14 (3–21)

NA

NA

FLU, CY, ATG ± TBI

NA

NA

NA

NA

NA

6

Esteves I [25] (2015)

Single-arm study

July 2010-August 2014

16

17 (5–39)

11/5

NA

CY + FLU+ TBI, FLU + ATG (2)

MMF, CsA, Cy

NA

19 (16–29)

21 (20–29)

NA

6

Gao L [40] (2014)

Single-arm study

June 2007-December 2010

26

25.4 (18–41)

NA

SAA/VSAA (16/10)

FLU, CY, ATG

CsA + MMF + MTX + ATG

NA

13 (11–19)

13 (10–21)

NA

5

Jennifer Clay [39] (2014)

Single-arm study

NA

8

NA

NA

NA

CY + FLU + TBI

MMF + FLU + PTCY

NA

18.5 (16–23)

26 (21–27)

NA

5

  1. Abbreviations: SAA severe aplastic anemia, VSAA very severe aplastic anemia, ATG antithymoglobulin, CsA cyclosporin A, MSCs bone marrow-mesenchymal stem cells, haplo-HSCT haplo-identical hematopoietic stem cell transplantation, BU busulfan, Cy cyclophosphamide, MMF mycophenolate mofetil, FLU fludarabine, MTX methotrexate, GVHD graft-versus-host disease, TBI total body irradiation